1,4-bis(4-bromothiophen-2-yl)butane-1,4-dione | 195062-50-1

• 分子结构分类: 有机化合物 - 有机氧化合物
• 英文名称: 1,4-bis(4-bromothiophen-2-yl)butane-1,4-dione
• 英文别名: 1,4-bis(4-bromo-2-thienyl)-1,4-butanedione
• CAS: 195062-50-1
• 化学式: C₁₂H₈Br₂O₂S₂
• 分子量: 408.134
• InChiKey: VRWKVVKWMUXMCN-UHFFFAOYSA-N

物化性质

• 沸点：
  522.1±50.0 °C(Predicted)
• 密度：
  1.816±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  4.3
• 重原子数：
  18
• 可旋转键数：
  5
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.17
• 拓扑面积：
  90.6
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  1,4-bis(4-bromothiophen-2-yl)butane-1,4-dione 在 正丁基锂 、 溶剂黄146 、 二异丙胺 作用下， 以 四氢呋喃 、 正己烷 为溶剂， 反应 2.5h， 生成 2,5-bis{4-bromo-5-[(1,1-dimethylethyl)dimethylsilyl]-2-thienyl}-1-octyl-1H-pyrrole
  参考文献：
  名称：

  间隔基扩展的Bis-Ene-Yne化合物：范围，局限性和属性

  摘要：

  噻吩对双烯炔化合物的裂解反应已得到系统地研究。这些多功能积木的便捷可及性为功能性有机材料中的新颖应用铺平了道路。

  DOI：

  10.1002/ejoc.201800446
• 作为产物：
  描述：

  1,4-双(2-噻吩基)-1,4-丁二酮 在 aluminum (III) chloride 、 溴 作用下， 以 氯仿 为溶剂， 反应 0.16h， 以87%的产率得到1,4-bis(4-bromothiophen-2-yl)butane-1,4-dione
  参考文献：
  名称：

  Direction of 3-bromothiophene acylation with succinyl chloride

  摘要：

  In the reaction of 3-bromothiophene with succinyl chloride in the presence of AlCl3, a mixture of three isomeric dibromo-substituted 1,4-di(2-thienyl)butane-1,4-diones was formed. The main component was the unsymmetrical 1-(3-bromo-2-thienyl)-4-(4-bromo-2-thienyl)butane-1,4-dione rather than 1,4-di-(3-bromo-2-thienyl)butane-1,4-dione expected according to the orientation rules.

  DOI：

  10.1007/s10593-013-1258-5

文献信息

• Gamma-diketones for treatment and prevention of aging skin and wrinkles
  申请人：Samumed, LLC

  公开号：US10434052B2

  公开（公告）日：2019-10-08

  The present disclosure relates to compounds having the following structure: or a dermatologically acceptable salt thereof, and cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.

  本公开涉及具有以下结构的化合物： 或其皮肤学上可接受的盐，以及包含这些化合物的化妆品或皮肤药物组合物，以及使用这些化合物或组合物治疗、保护和/或改善皮肤状况和/或美学外观的方法，例如，治疗、预防、改善、减少和/或消除皮肤细纹和/或皱纹，或改善皮肤细纹和/或或皱纹的外观，包括应用所公开的化合物或组合物。
• GAMMA-DIKETONES FOR TREATMENT AND PREVENTION OF AGING SKIN AND WRINKLES
  申请人：Samumed, LLC

  公开号：US20160206540A1

  公开（公告）日：2016-07-21

  The present disclosure relates to compounds, cosmetic or dermopharmaceutical compositions comprising the same, and methods for using the compounds or compositions for treating, protecting, and/or improving the condition and/or aesthetic appearance of skin, for example, treating, preventing, ameliorating, reducing and/or eliminating fine lines and/or wrinkles of skin, or improving the appearance of fine lines and/or or wrinkles of skin comprising application of the compounds or compositions disclosed.
• GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS
  申请人：Samumed, LLC

  公开号：US20170260176A1

  公开（公告）日：2017-09-14

  The present disclosure provides γ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.
• US9795550B2
  申请人：——

  公开号：US9795550B2

  公开（公告）日：2017-10-24
• [EN] GAMMA-DIKETONES AS WNT/BETA -CATENIN SIGNALING PATHWAY ACTIVATORS<br/>[FR] GAMMA-DICÉTONES EN TANT QU'ACTIVATEURS DE LA VOIE DE SIGNALISATION WNT/&Bgr;-CATÉNINE
  申请人：SAMUMED LLC

  公开号：WO2014130869A1

  公开（公告）日：2014-08-28

  The present disclosure provides ƴ-diketones or analogs thereof, that activate Wnt/β-catenin signaling and thus treat or prevent diseases related to signal transduction, such as osteoporosis and osteoarthropathy; osteogenesis imperfecta, bone defects, bone fractures, periodontal disease, otosclerosis, wound healing, craniofacial defects, oncolytic bone disease, traumatic brain injuries or spine injuries, brain atrophy/neurological disorders related to the differentiation and development of the central nervous system, including Parkinson's disease, strokes, ischemic cerebral disease, epilepsy, Alzheimer's disease, depression, bipolar disorder, schizophrenia; otic disorders like cochlear hair cell loss; eye diseases such as age related macular degeneration, diabetic macular edema or retinitis pigmentosa and diseases related to differentiation and growth of stem cell, such as hair loss, hematopoiesis related diseases and tissue regeneration related diseases.